Evidence map›Paper›PMID 42398129›Full record

ReviewBreast (Edinburgh, Scotland)2026

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Mariana Carvalho Gouveia, Pedro José Galvão Freire, Caio Guilherme Souza Prado, Caio Abner Leite, Bruna Migliavacca Zucchetti, Renata Colombo Bonadio, Carlos Barrios, Adriana Kahn, Maryam Lustberg, Romualdo Barroso-Sousa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mariana Carvalho GouveiaYale Cancer Center, Yale School of Medicine, New Haven, United States, 333 Cedar Street, New Haven, CT, 06510, United States.
Pedro José Galvão FreireClinical Oncology, Rede D'Or, Recife, Brazil, Avenida Agamenon Magalhães, 4760, Ilha do Leite, Recife, PE, 50070-160, Brazil.
Caio Guilherme Souza PradoClinical Oncology, Cancer Institute of the State of São Paulo- ICESP, University of São Paulo- USP, São Paulo, Brazil, Avenida Dr. Arnaldo, 251, Cerqueira César, São Paulo, SP, 01246-000, Brazil.
Caio Abner LeiteClinical Oncology, Brasília Hospital - Américas Oncologia, Brasília, Brazil, St. de Habitações Individuais Sul QI 15, Lago Sul, Brasília, DF, 70390-700, Brazil.
Bruna Migliavacca ZucchettiClinical Oncology, Hospital 9 de Julho- Américas Oncologia, São Paulo, Brazil, Rua Peixoto Gomide, 545, Bela Vista, São Paulo, SP, 01309-001, Brazil.
Renata Colombo BonadioClinical Oncology, Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil, Avenida República do Líbano, 2267, Ibirapuera, São Paulo, SP, 04501-000, Brazil.
Carlos BarriosLatin American Cooperative Oncology Group, Porto Alegre, Brazil, Rua Mostardeiro, 777, Moinhos de Vento, Porto Alegre, RS, 90430-001, Brazil.
Adriana KahnYale Cancer Center, Yale School of Medicine, New Haven, United States, 333 Cedar Street, New Haven, CT, 06510, United States.
Maryam LustbergYale Cancer Center, Yale School of Medicine, New Haven, United States, 333 Cedar Street, New Haven, CT, 06510, United States.
Romualdo Barroso-SousaClinical Oncology, Brasília Hospital - Américas Oncologia, Brasília, Brazil, St. de Habitações Individuais Sul QI 15, Lago Sul, Brasília, DF, 70390-700, Brazil. Electronic address: romualdo.sousa.ext@americasmed.com.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) have redefined therapeutic paradigms in metastatic breast cancer, offering unprecedented efficacy across hormone receptor-positive/HER2-negative and triple-negative subtypes. Trastuzumab deruxtecan, sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan are expanding treatment options beyond traditional chemotherapy. As their clinical integration advances, optimizing the prevention and management of ADC-related toxicities, determining optimal sequencing strategies, and refining biomarker characterization have become central challenges. Ongoing research into ADC combinations, earlier-line use, and precision biomarker selection is expected to further reshape the therapeutic landscape and personalize care for patients with advanced breast cancer.

Indexed as

Antibody–drug conjugatesBreast cancer

Identifiers

PMID42398129
PMCPMC13355787

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.